Cardiovascular causes accounted for nearly 40% of deaths among study patients age 22 to 29 years at onset of treatment for kidney failure.
Based on current data, AAP Board of Directors says either injection or nasal spray vaccination is okay.
Novo Nordisk has submitted 2 New Drug Applications (NDAs) for oral semaglutide as well as a supplemental NDA (sNDA) for subcutaneous (SC) semaglutide (glucagon-like peptide-1; Ozempic).
Researchers found a low rate of recurrent stroke after carotid and vertebral dissection and no difference between antiplatelet agents and anticoagulants.
Incidence of major cardiac implantable electronic device infections significantly lower with envelope.
Data show 47 percent reduction in risk for rehospitalization for HF symptoms with device implantation
High-risk human papillomavirus infection may be associated with the risk for cardiovascular disease in Korean women.
The CAROLINA trial met its primary endpoint, demonstrating no increased CV risk with linagliptin, a DPP-4 inhibitor, when compared with glimepiride, a sulfonylurea, in patients with type 2 diabetes and CV risk.
Investigators evaluated whether treatment with one year of oral or transdermal administration of estrogen plus cyproterone and transdermal or intramuscular application of testosterone caused changes in serum lipids and blood pressure.
Maternal use of ondansetron during the first trimester of pregnancy was not found to be associated with cardiac or congenital malformation in offspring but may be linked to oral cleft development.